MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...
A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in ...
Press ReleaseIB Communicationsbracco@ibcomms.agency Bracco Enters Cell Therapy Manufacturing with Cell Selection and Activation TechnologiesTechnology based on Bracco’s clinically validated ...
Bracco’s cell selection and activation microbubble technology is designed to support both positive- and negative-selection strategies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results